Siro Diagnostics

Siro is developing a pocket-sized, simple, and fast sample-to-answer multiplex point-of-care diagnostic solution. Our proven technology is supported by a robust, comprehensive IP portfolio, and a state-of-the-art, vertically integrated R&D and fully automated manufacturing capability. The first multiplex product (Flu A, Flu B, COVID) will enter clinical trials in Q1 2026, followed by a second product (Flu A, Flu B, COVID, RSV) entering trials in Q4 2026.

Contact

© 2025 Siro Diagnostics Inc. All Rights Reserved.

This website contains forward-looking statements, including without limitation statements regarding product development, clinical timelines, regulatory plans, and manufacturing capabilities. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Siro undertakes no obligation to update these statements.